Edwards Lifesciences Corporation
HealthcareNYSE:EW · New York Stock Exchange
-$1.03 today
Vol 2.19M · Avg 5.38M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$6.3B of revenue converted into $1.1B of net income for the selected period. Gross margin is 78.0% and net margin is 17.3%, showing how much revenue survives after costs and taxes. EPS is $1.88, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.1B +11.5% | $5.4B +8.6% | $5.0B -6.9% | $5.4B +2.9% | $5.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.3B +18.7% | $1.1B +7.7% | $1.0B -11.1% | $1.2B -4.8% | $1.2B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $4.7B +9.7% | $4.3B +8.8% | $4.0B -5.8% | $4.2B +5.2% | $4.0B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 78.1% -1.3pp | 79.5% +0.2pp | 79.3% +1.0pp | 78.3% +1.7pp | 76.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.1B +2.5% | $1.1B +9.4% | $962.9M +1.9% | $945.2M +4.7% | $903.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $2.1B +16.5% | $1.8B +13.1% | $1.6B +1.0% | $1.6B +5.0% | $1.5B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $3.1B +5.5% | $2.9B +15.6% | $2.5B +1.3% | $2.5B +4.9% | $2.4B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $156.6M +0.9% | $155.2M +7.1% | $144.9M -13.1% | $166.8M +2.1% | $163.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | $1.4B -17.0% | $1.7B +12.3% | $1.5B -21.7% | $2.0B +3.7% | $1.9B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 23.6% -8.1pp | 31.7% +1.0pp | 30.6% -5.8pp | 36.4% +0.3pp | 36.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $1.6B +18.7% | $1.4B -3.4% | $1.4B -16.2% | $1.7B +5.7% | $1.6B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 27.0% +1.6pp | 25.3% -3.1pp | 28.5% -3.1pp | 31.6% +0.9pp | 30.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $148.4M +23.4% | $120.3M +79.0% | $67.2M +89.3% | $35.5M +104.0% | $17.4M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $19.8M +12.5% | $17.6M -32.8% | $26.2M +5.6% | $24.8M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$363.3M -314.5% | $169.4M +408.6% | -$54.9M -184.5% | $65.0M -29.0% | $91.6M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $1.3B -17.8% | $1.5B +12.8% | $1.4B -22.3% | $1.8B +3.8% | $1.7B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 21.0% -7.5pp | 28.5% +1.1pp | 27.4% -5.4pp | 32.8% +0.3pp | 32.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $216.9M +42.6% | $152.1M -0.2% | $152.4M -37.9% | $245.5M +23.4% | $198.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | $1.1B -74.3% | $4.2B +197.7% | $1.4B -7.9% | $1.5B +1.3% | $1.5B | $4.9B | $4.8B | $4.7B |
| Net Margin | 17.7% -59.1pp | 76.7% +48.8pp | 28.0% -0.3pp | 28.3% -0.5pp | 28.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 -73.6% | $7 +202.2% | $2 -6.1% | $2 +2.1% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 -73.7% | $7 +203.0% | $2 -5.7% | $2 +2.5% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $584.8M -2.2% | $597.7M -1.5% | $606.7M -2.0% | $619.0M -0.7% | $623.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $585.8M -2.3% | $599.3M -1.7% | $609.4M -2.4% | $624.2M -1.1% | $631.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
argenx SE
NASDAQ:ARGX
$55.60B
Becton, Dickinson and Company
NYSE:BDX
$52.82B
Cardinal Health, Inc.
NYSE:CAH
$52.35B
Haleon plc
NYSE:HLN
$40.28B
Agilent Technologies, Inc.
NYSE:A
$36.52B
Alcon Inc.
NYSE:ALC
$32.50B
DexCom, Inc.
NASDAQ:DXCM
$28.77B
Veeva Systems Inc.
NYSE:VEEV
$25.79B
STERIS plc
NYSE:STE
$20.29B
Bruker Corporation
NASDAQ:BRKR
$8.16B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EW generate?
Edwards Lifesciences Corporation (EW) reported $6.07B of revenue in fiscal 2025.
Is EW profitable?
Edwards Lifesciences Corporation (EW) reported $1.07B of net income, with a net margin of 17.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.